Connect with us

Technology

WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership

Published

on

SHANGHAI, Sept. 16, 2026 /PRNewswire/ — Forbes China recently released the 2026 Forbes China ESG 50 list. WuXi Biologics was named to the list for its outstanding performance in sustainable development, Green CRDMO solutions and ESG digital innovation, and was highlighted by Forbes China as one of the representative companies in ESG data governance.

The 2026 Forbes China ESG 50 list starts with an initial candidate pool composed of the Chinese companies included in the Forbes Global 2000, and then selects 50 companies with outstanding ESG performance and leading practices across environmental, social and governance dimensions. This year’s list is built around three core themes: enhanced disclosure granularity, advanced compliance strategies, and the use of technology tools, including AI. Company practices are systematically reviewed across sectors such as finance, manufacturing, energy, technology, consumer goods and healthcare, with a focus on demonstrated innovation in data governance, global compliance capabilities and AI-enabled sustainable development.

Forbes China highlighted that data governance has become an essential capability for companies to achieve quantified ESG management, traceability and continuous improvement. In its list analysis, the publication noted that WuXi Biologics has established a comprehensive ESG data governance system covering its global operations. The Company achieved a 30% reduction in Scope 1 and Scope 2 greenhouse gas emission intensity compared with 2020, and reduced water intensity by 32% compared with 2019, exceeding its original 30% target.

As a leading global CRDMO, WuXi Biologics has deeply embedded sustainable development into its corporate strategy. Guided by the Green CRDMO strategy, the Company is committed to creating environmental and social value through innovative technologies and operational excellence, empowering global partners to advance their own sustainability goals. Across governance, environmental and social dimensions, WuXi Biologics integrates ESG principles into biologics research, development, manufacturing, supply chain management and global business operations, contributing to the green transformation of the biopharmaceutical industry.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of the ESG Committee, said: “WuXi Biologics’ inclusion in the 2026 Forbes China ESG 50 list is a recognition of the Company’s long-standing commitment to sustainable development, deepening Green CRDMO practices and ESG digital innovation. Sustainability has been deeply embedded in our corporate strategy and global operations. Green CRDMO is not only our long-term commitment, but also an important pathway to empowering client growth and unlocking green business value. Looking ahead, we will continue to advance innovation-driven and sustainable development, strengthen ESG governance capabilities and operational resilience, and work with global partners to promote green development across the industry, creating long-term sustainable value together.”

Sustainability Strategy and Governance

To support strategic execution, WuXi Biologics has established a four-tier ESG governance structure, comprising the ESG Committee, made up of Board members to provide oversight; the ESG Steering Group, composed of senior management to offer key insights; a dedicated ESG function to drive implementation; and issue-specific task forces to advance actions across key topics. This structure forms a closed-loop management mechanism from strategic decision-making and target management to execution feedback. The Company aligns with the United Nations Sustainable Development Goals (UN SDGs) and — based on the characteristics of the healthcare industry and stakeholder priorities — fosters systematic management across topics such as healthcare access, technology innovation, product quality, climate change, responsible manufacturing, employee development, business ethics, and a sustainable supply chain.

Through target matrices, performance tracking, risk identification and ongoing communication, WuXi Biologics continues to enhance the transparency and execution of its sustainability governance as it advances ESG management from qualitative disclosure to quantitative tracking, using more granular data to support target management, performance evaluation and continuous improvement.

This governance system also echoes the observations made by Forbes China regarding the material topics prioritized by the listed companies. According to Forbes China, companies on the list generally place strong emphasis on climate change, occupational health and safety, product safety and quality, data security and privacy, supply chain security, and compliance operations. In the healthcare sector, climate change, product safety, occupational health, and data security are among the most closely watched topics. WuXi Biologics’ continuous strengthening of management mechanisms around these key areas — supporting implementation through digital data governance, global compliance management and green operations capabilities — is a reflection of its systematic approach and long-term commitment to core sustainability topics in the healthcare industry.

Green CRDMO Solution

Building on its clear sustainability governance structure and material topic management, WuXi Biologics translates strategic requirements into concrete Green CRDMO practices that span biologics research, development, manufacturing and global business operations. Through innovative technologies, process optimization and green operations, the Company successfully integrates environmental performance improvement, operational efficiency and customer value creation, continuously empowering global partners to pursue more resilient sustainability goals.

In green research, WuXi Biologics helps its global partners shorten the path from molecule to patient, and this greater efficiency also leads to a reduction in environmental impact. The WuXiBody™ bispecific antibody platform serves as an example. With this platform, the Company enhances molecular developability and stability while reducing environmental impact by shortening R&D cycles and lowering the natural resources and energy required to maintain development conditions. In green development and manufacturing, the WuXiUI™ ultra-intensified fed-batch production technology platform can improve production efficiency by 3–8 times and reduce life-cycle environmental impact by up to 60% compared with traditional fed-batch processes. The Company also leverages the advantages of single-use technology for biologics manufacturing, which can save up to 70% of water consumption, reduce resource consumption by approximately 33%, and lower the negative impact on climate change by approximately 40% compared with traditional stainless-steel processes. The combination of WuXiUI™ and single-use technology can reduce the product carbon footprint by up to 80%, accelerating the transition of green manufacturing from concept to scalable practice.

In green operations, the Company — guided by its SBTi-based GHG emission reduction targets — advances carbon reduction, water conservation and waste reduction through lean management. In addition, it shares 242 outstanding energy-saving cases through its WuXi Biologics Green CRDMO White Paper to promote the replication of green operations practices across global sites and the broader industry value chain. The Green CRDMO solution was also selected as one of the United Nations Global Compact “20 Case Examples for Sustainable Development Over 20 Years,” further demonstrating the Company’s leadership in empowering industry-wide transformation through green technology innovation.

ESG Digital Innovation

In addition to deepening ESG practices, WuXi Biologics actively applies digital and AI technologies to sustainable development management. The Company has independently developed a digital Smart ESG platform that supports refined and standardized information collection and governance across environmental, social and governance topics, covering annual carbon inventory, energy and water use, waste management, talent development, supply chain management and volunteer activities. The platform shifts ESG information across global sites from decentralized reporting to systematic accumulation, allowing for continuous improvement in quality, traceability and collaboration efficiency.

In daily operations, WuXi Biologics uses digital dashboards to dynamically monitor and centrally visualize key ESG indicators, facilitating timely visibility into site-level performance, target progress and anomalies, and providing transparent and comparable evidence for performance evaluation, operational optimization and management decision-making. For product life-cycle environmental impact and carbon footprint management, the Company — having transformed complex environmental impact assessments into an efficient, accurate and traceable solution — has further developed digital modules to support clients in advancing Scope 3 management and value chain decarbonization, and strengthening long-term competitiveness in green procurement.

WuXi Biologics has received international recognition over the years for its sustainable development performance, including the highest MSCI AAA ESG Rating; the EcoVadis Platinum Medal, placing the Company in the top 1% globally; inclusion in the Dow Jones Best-in-Class World Index and Best-in-Class Emerging Markets Index; inclusion on CDP’s A Lists for Climate Change, Water Security and Supplier Engagement Assessment; Morningstar Sustainalytics’ highest “Negligible Risk” ESG rating, and identification as an industry and regional ESG leader; and inclusion in the FTSE4Good Index Series and the Hang Seng Corporate Sustainability Benchmark Index. These recognitions reflect not only the Company’s continued progress across environmental, social and governance dimensions, but also global stakeholders’ acknowledgment of WuXi Biologics’ sustainability strategy, governance capabilities and practical achievements.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide*.

With over 14,000 employees in China, the United States, Ireland, Germany, and Singapore, including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence, WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients’ needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of June 30, 2026, WuXi Biologics is supporting 1064 integrated client projects, including 78 in Phase III and 28 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

*The winner of the “2026 Biologics CDMO of the Year” (Large CDMOs) (Life Science Connect / Outsourced Pharma)
*The winner of the “2026 Best Contract Development & Manufacturing Organization Award” (ABEA)

Contacts

ESG
esg@wuxibiologics.com

Media
PR@wuxibiologics.com

View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-named-to-forbes-china-esg-50-list-2026-for-green-crdmo-and-digital-esg-leadership-302880381.html

SOURCE WuXi Biologics

Continue Reading

Technology

Nozomi Networks Introduces Nozomi Compass to Modernize the Everyday Work of OT Asset and Service Management

Published

on

By

Pairs the industry’s deepest first-party OT asset data to guide OT-safe change and remediation workflowsDelivers continuous compliance evidence, safer change governance, and real risk reductionEmpowers critical infrastructure operators to act, and prove they acted, at the speed the AI-risk era demands

SAN FRANCISCO, Sept. 16, 2026 /PRNewswire/ — Nozomi Networks, the leader in operational technology (OT), Internet of Things (IoT), and cyber-physical systems (CPS) security, today announced Nozomi Compass, an OT-native asset and service management platform built for a new reality. AI has collapsed the time it takes to discover vulnerabilities, anomalies, and exposures across industrial environments from months to minutes. Yet, acting on them still runs through spreadsheets, IT ticketing tools, and manual processes never designed for OT. Nozomi Compass closes that gap. 

“Nozomi Compass underpins our vision to provide a single source of truth for visibility, threat detection, governed workflows, compliance evidence, and trusted AI-enabled operational decision-making,” said Andrea Carcano, CEO and Co-Founder of Nozomi Networks. “Until now, operators have been working with an ineffective IT-native toolset to service their OT assets. As industrial organizations incorporate AI automation to keep pace with today’s threat and regulatory landscape, they cannot live in the unknown. Compass is the foundation that allows teams to move quickly with confidence.”

Built on Nozomi’s real-time, first-party asset data, Compass gives industrial organizations a real-time OT system of record and process-safe workflows to plan, approve, execute, and prove every change. As vulnerability discovery continues to outpace manual remediation, this framework of unified CPS security and OT service management gives industrial organizations the source of truth they need. It is the foundation for safely adopting autonomous and agentic OT and IoT workflows grounded in real operational and threat context with a human always part of the process. Nozomi Compass turns AI-speed action into governed, auditable outcomes without risking uptime or safety.

Key capabilities of Nozomi Compass will include:

A trusted OT system of record: Built on Nozomi’s real-time, first-party OT and IoT asset data, replacing stale spreadsheets, imported records, and IT-first configuration databases with a single current source of truth.OT-native workflows: Purpose-built for how industrial environments operate, incorporating OT-safe processes, Purdue-level relationships, safety criticality, and full lifecycle history into every asset record and workflow logic.Governed change and risk decisions: Live risk and safety context, traceable approvals, consequence-based risk scoring, and compensating controls create a defensible record of what was authorized, changed, and completed.Continuous compliance evidence: Audit-ready evidence mapped to frameworks including NERC CIP, IEC 62443, NIS2 and TSA, generated continuously to reduce manual effort.An open foundation for enterprise workflows and AI: Governed OT data flows into the EAM, CMDB, ITAM, ITSM, SIEM and SOAR tools customers already run, while giving AI-driven tools the clean, contextual OT data they need to operate safely.

Nozomi Compass marks the next step in Nozomi’s platform vision to unify cyber-physical systems security and operational technology service management on a single foundation that gives customers the confidence they understand what is happening across their operational environment and control what happens next. Rather than retrofitting a generic IT platform for OT service management, Compass is built directly on the same real-time asset intelligence that powers Vantage, Nozomi’s cyber-physical security platform, giving customers a unified, current system of record and action.

“OT and IT service management have always spoken different languages,” said Moreno Carullo, Co-founder and CTO at Nozomi Networks. “Nozomi Compass is purpose-built around how industrial operations work, including safety windows, process dependencies, and physical consequences, so teams can finally govern change and prove compliance without forcing OT data into an IT-shaped box.”

Nozomi Compass will be available to Nozomi Networks customers in January. For more information visit the Nozomi Compass page.

About Nozomi Networks
Nozomi Networks protects the world’s critical infrastructure from cyber threats. Our platform uniquely combines network and endpoint visibility, threat detection, and AI-powered analysis for faster, more effective incident response. Customers rely on us to minimize risk and complexity while maximizing operational resilience. www.nozominetworks.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nozomi-networks-introduces-nozomi-compass-to-modernize-the-everyday-work-of-ot-asset-and-service-management-302879951.html

SOURCE Nozomi Networks

Continue Reading

Technology

Nona Biosciences Successfully Develops World’s First Language Model Trained on Fully Human Heavy-Chain-Only Antibodies

Published

on

By

CAMBRIDGE, Mass., Sept. 16, 2026 /PRNewswire/ — Nona Biosciences (“Nona”), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, today announced the development of HCAbLM, the world’s first language model specifically trained on fully human heavy-chain-only antibodies (HCAbs). HCAbLM was built on a large-scale repertoire comprising 31.8 million fully human HCAb sequences from 73 independently immunized HCAb transgenic mice. The study, “A foundation model learns the sequence and functional grammar of fully human heavy-chain-only antibodies,” was published in bioRxiv.

From Binder to Drug Candidate: A Leap in AI Antibody Development

The main bottleneck in the current AI antibody field is no longer “whether an antibody that binds the target can be designed,” but rather “whether the designed antibody can be manufactured at scale, whether it will aggregate, and whether it is stable”—that is, developability. HCAbLM was created precisely to address this issue. The model has learned the “sequence grammar” unique to fully human HCAbs—a set of underlying rules that determine whether an antibody can fold, exist stably, and ultimately become a drug. Conventional general-purpose models cannot capture this set of rules because their training data contain almost no HCAb sequences. HCAbLM fully demonstrates that a dedicated model trained on unique antibody sequence data can better translate sequence space cognition into developability prediction.

A Dedicated HCAb Model Outperforms General-Purpose Protein and Antibody Models

The representations learned by HCAbLM demonstrate transferability to experimentally measured antibody properties, including size exclusion chromatography (SEC) purity, hydrophobic interaction chromatography (HIC) behavior, and thermal stability, highlighting HCAbLM’s potential in the evaluation and optimization of fully human HCAbs, going beyond mere sequence analysis.

In public benchmarks for cross-project developability prediction, HCAbLM, with only 366 million parameters, surpassed general-purpose protein large models including Meta’s ESM-6B with 6 billion parameters, as well as previously leading antibody language models IgLM and AbLang, on two core metrics: SEC purity and HIC behavior.

The development of HCAbLM marks an important advancement in Nona’s application of artificial intelligence (AI) to antibody discovery and development. By combining large-scale antibody repertoires with AI-driven modeling, Nona is building a foundation for more efficient and data-driven antibody design and developability assessment.

“The development of HCAbLM represents an important step in our efforts to apply AI to specialized antibody formats and unlock the value of large-scale antibody repertoires,” said Dr. Di Hong, Chief Executive Officer of Nona Biosciences. “By learning the unique sequence characteristics of fully human HCAbs and demonstrating transferability to experimentally measured molecular properties, HCAbLM provides a new foundation for AI-enabled antibody discovery and development. We look forward to further integrating HCAbLM with Nona’s technology platforms, and leveraging these capabilities to accelerate antibody discovery and development while empowering our partners to unlock new opportunities for next-generation biotherapeutics.”

About Nona Biosciences

Nona Biosciences, a wholly owned subsidiary of HBM Holding Limited (HKEX:02142), is a global biotechnology company committed to advancing biotherapeutic innovation through cutting-edge technology platforms and integrated solutions. Nona supports programs with its I to I® framework, from early-stage ideas through preclinical research and advancement toward IND and early clinic, spanning target validation and antibody discovery to early development.

Nona’s proprietary Harbour Mice® technology platform generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain-only (HCAb) format. The HCAb Harbour Mice® is the world’s first fully human HCAb transgenic mouse with clinical validation. This unique platform offers exceptional versatility for diverse applications using fully human VH single-domain antibodies as a plug-and-play system, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.

By integrating Harbour Mice®, single-B cell screening technology, NonaCarFx™ (a direct CAR-function-based screening platform), Hu-mAtrIx™ (an AI-driven drug discovery platform), Modalities-on-Demand® (a next-generation modalities solution), and end-to-end preclinical drug development services, Nona Biosciences is dedicated to driving the global invention of transformative next-generation drugs. For more information, please visit: www.nonabio.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nona-biosciences-successfully-develops-worlds-first-language-model-trained-on-fully-human-heavy-chain-only-antibodies-302880444.html

SOURCE Nona Biosciences

Continue Reading

Technology

Moldova eGovernance Agency Launches Banking Use of EVO Digital Identity Credentials Built to European Standards

Published

on

By

CHISINAU, Moldova, Sept. 16, 2026 /PRNewswire/ — Digital credentials from EVO, Moldova’s integrated government app, are now accepted by four of the country’s banks: Moldindconbank, FinComBank, EuroCreditBank and Victoriabank, allowing clients to identify themselves through EVO. This marks a broader expansion across the public and private sectors, as Moldova moves to make secure digital identity a standard way to access services nationwide while aligning with Europe’s emerging digital identity ecosystem. Developed in line with the European Digital Identity Wallet framework, EVO is being built to support secure, consent-based and interoperable digital identity transactions, including future cross-border use.

The integration turns the digital documents already available in EVO into reusable credentials for everyday interactions with private-sector services. Identity is confirmed by scanning a QR code and choosing to share the information the bank requests. The verified data is transferred digitally, eliminating the need to present or photocopy a physical identity document and reducing manual data entry.

The eGovernance Agency opened EVO integration to public and private organizations on April 1, 2026. Since then, the ecosystem has expanded beyond the first banking integrations, with 30 relying parties at different stages of connection, including one of Moldova’s largest telecommunications operators and the National Bank of Moldova. At least 20 organizations are expected to be operationally integrated by the end of 2026.

“Digital credentials become valuable when people can actually use them in real-life scenarios, and we’re aiming for ubiquity. Banks are among the institutions where trusted identification matters most, so bringing EVO into everyday banking is an important milestone. Our next step is to expand this ecosystem across both the public and private sectors, while ensuring that what we build in Moldova is compatible with the digital identity infrastructure being developed across Europe,” said Nicoleta Colomeeț, Director of the Moldova eGovernance Agency.

From national rollout to European interoperability

Moldova is developing EVO Wallet in line with European Digital Identity Wallet standards, while contributing its experience in digital credentials to their implementation, testing and cross-border interoperability. As a member of the WE BUILD consortium, Moldova works alongside European partners to validate digital identity credentials and help identify and resolve differences between national implementations. EVO has successfully tested its digital ID in the European PID format and its digital driving licence in the ISO mDL format with partners from France, Hungary, Austria and Belgium, while further interoperability testing in Moldova brought together teams from France, the Netherlands, Croatia, Romania and Ukraine.

For Moldova, an EU candidate country, digital identity is part of a broader transition toward European digital infrastructure. Following integration into initiatives such as SEPA and “Roam Like at Home”, the development of an interoperable digital identity wallet extends that process to how citizens identify themselves and securely share verified information.

The Moldova eGovernance Agency leads the development of Moldova’s digital public infrastructure and the transformation of public services. It develops and operates the national digital platforms that let citizens, businesses and public institutions interact securely online. Its work supports Moldova’s European integration and transition to fully digital public services. EVO test certificates and the integration guide are available on the egov4dev public integration page.

View original content to download multimedia:https://www.prnewswire.com/news-releases/moldova-egovernance-agency-launches-banking-use-of-evo-digital-identity-credentials-built-to-european-standards-302880446.html

SOURCE Moldova eGovernance Agency

Continue Reading

Trending